Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT) (AVERT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02483429 |
Recruitment Status :
Active, not recruiting
First Posted : June 29, 2015
Last Update Posted : August 12, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Vertigo Dizziness | Device: VRT Care | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 195 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Diagnostic |
Official Title: | Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT) |
Actual Study Start Date : | December 4, 2017 |
Estimated Primary Completion Date : | August 31, 2024 |
Estimated Study Completion Date : | August 31, 2025 |

Arm | Intervention/treatment |
---|---|
Experimental: VRT Care
Patients randomized to VRT (VOG-guided Rapid Triage) care will have an algorithm-determined patient-specific diagnosis and treatment pathway in the emergency department. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
|
Device: VRT Care
The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
Other Name: GN Otometrics (Instrumentation & Control Systems, Inc) |
No Intervention: Standard of Care (SOC)
Patients randomized to Standard of Care will undergo usual emergency department care without revealing results of VOG testing. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
|
|
No Intervention: Observational
Patients who signed an informed consent but did not meet inclusion/exclusion criteria and don't randomize will enter a parallel track observational sub-study with limited 1 and 6 month phone follow-up.
|
- Six-Category Diagnosis Accuracy (all, VRT vs. SOC) [ Time Frame: 6 months after last patient/last visit ]Total diagnosis accuracy VRT vs. SOC using 30-day adjudicated final diagnoses categorized in one of six possible diagnosis categories (3 peripheral, 1 central, 1 medical/other, 1 non-diagnosis). We will use "Index VRT Diagnosis" and "ED Physician Diagnosis" compared to the "Adjudicated Final Diagnosis" based on ED index visit and 30-day follow-up clinical assessments. Also analyzed for each diagnosis category will be sensitivity, specificity, predictive values, likelihood ratios.
- Index Visit Total Diagnostic Utilization Costs (all, VRT vs. SOC) [ Time Frame: 6 months after last patient/last visit ]Total dollar costs VRT vs. SOC for diagnostic tests and consultations obtained during the ED index visit and hospital admission (for those admitted at the index visit). For the VRT arm, this does not include costs of protocol safety MRIs or any tests ordered off-protocol by ED physicians. It does include tests ordered on-protocol by consultants or ED physicians in the VRT 'equivocal' pathway. Total costs will be calculated by multiplying fixed cost estimates (most recent year available average Medicare reimbursement in US dollars) by utilization rates for each ED index visit service tracked.
- Odds of Short-Term Serious Medical Events (SMEs) after Misdiagnosis (SOC arm only, correct vs. incorrect diagnoses) [ Time Frame: 9 months after last patient/last visit ]We will use 30-day adjudicated final diagnoses categorized in one of six possible categories to determine "correct" vs. "incorrect" diagnoses. We will consider SMEs occurring between the time of ED index visit disposition and 1-week research follow-up visit. Events diagnosed at the ED index visit will not be counted. Events newly diagnosed at the 1-week follow-up or in the interval prior to follow-up will be counted, regardless of their relatedness to the ED index dizziness symptoms, with the exception of test or treatment complications. Diagnostic test or treatment complications must be related directly or indirectly to the dizziness symptoms. To avoid 'double counting' misdiagnoses as SMEs that are pursuant to misdiagnosis, 1-week stroke diagnoses not rendered at the ED index visit will not be counted as SMEs unless neurologic or vestibular symptoms/signs worsen after ED index discharge.
- Expert VOG Six-Category Diagnosis Accuracy (all, expert VOG vs. SOC) [ Time Frame: 6 months after last patient/last visit ]Total diagnosis accuracy adjudicated expert VOG diagnosis vs. SOC using 30-day adjudicated final diagnoses categorized in one of six possible diagnosis categories (3 peripheral, 1 central, 1 medical/other, 1 non-diagnosis). We will use "Index VOG Diagnosis" and "ED Physician Diagnosis" compared to the "Adjudicated Final Diagnosis" based on ED index visit and 30-day follow-up clinical assessments. This outcome measure reflects the theoretical maximum diagnostic accuracy performance (i.e., expert level) of any future algorithms.
- Stroke-No Stroke Diagnosis Accuracy (all, VRT vs. SOC) [ Time Frame: 6 months after last patient/last visit ]Total diagnosis accuracy VRT vs. SOC using 30-day adjudicated final diagnoses categorized as stroke vs. no stroke (posterior fossa mass lesion, encephalitis, etc.). Also analyzed for the stroke diagnosis category will be sensitivity, specificity, predictive values, likelihood ratios.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Adult (18 years and older) ED patients with all of the following (all determined pre-randomization):
VESTIBULAR SYMPTOMS: presenting symptom of "vertigo" OR "dizziness" OR "unsteadiness" (as defined by consensus expert definitions in the International Classification of Vestibular Disorders).
RELEVANT EXAM SIGNS*: pathologic nystagmus (spontaneous, gaze-evoked, or positional) by bedside VOG testing OR pathologic ataxia (gait, trunk, stance, limbs) by bedside ataxia examination.
RECENT ONSET: symptoms AND signs* appear to be new or markedly worse in the past month
* Exam signs are required for randomization, but not for the observational arm
Exclusion Criteria
-
Excluded from Pre-Randomization Screening
Level 1 trauma or critical illness Altered mental status (e.g., delirium, dementia) that would preclude active study participation (this includes patients with abnormal mental state due to alcohol intoxication or illicit substance, which are known, easily-recognized causes of dizziness or vertigo presentations to the ED) Non-English speaking (enrollment of non-English speakers is not feasible given the logistics of identifying a translator and the need for rapid recruitment and randomization in the AVERT study; furthermore, the terms vertigo, dizziness, and unsteadiness may have different meanings in other languages) Known pregnancy (all women of childbearing age who are enrolled will undergo a urine or serum beta-HCG pregnancy test prior to MRI to confirm no pregnancy, per local institutional guidelines)
Unable or unsafe to participate in screening, including VOG tests (as deemed by specific pre-enrollment risk assessment questions or ED provider and/or Study Coordinator judgment) including, but not limited to:
visual impairment sufficient to prevent visual fixation during the VOG testing clinically-perceived risk to patient of participating in study (ED provider or staff concerns) clinically-perceived risk to research staff (e.g., violence, blood/body fluid/respiratory precautions) unstable cardiac status (given a single reported case of bradycardia with impulse testing) acute cranio-cervical trauma or other condition (e.g., rheumatoid arthritis) that might lead to instability of the cervical spine that would be a contraindication to neck rotation during VOG testing Obvious general medical cause (as judged by treating ED provider) including, but not limited to, acute myocardial infarction, pulmonary embolus, pneumonia, urinary tract infection, drug intoxication, etc.
- Excluded from Randomization (Eligible for Observational Arm Follow-up)
Patient previously randomized in the AVERT Trial (previously screened but not randomized are eligible)
Unable to participate fully with study follow-up (particularly MRI) including, but not limited to:
unable to return for follow-up testing within 30 days unable to undergo MRI because of contraindications (e.g., pacemaker, metallic foreign body, pregnancy) or other reasons (severe claustrophobia, too large or too heavy for MRI scanner)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02483429
United States, Illinois | |
University of Illinois | |
Peoria, Illinois, United States, 61656 | |
United States, Maryland | |
Johns Hopkins Hospital - Bayview | |
Baltimore, Maryland, United States, 21224 | |
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
United States, Michigan | |
University of Michigan | |
Ann Arbor, Michigan, United States, 48109 | |
United States, New York | |
Mt. Sinai Medical Center | |
New York, New York, United States, 10029 |
Principal Investigator: | David Newman-Toker, MD, PhD | Johns Hopkins University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT02483429 |
Other Study ID Numbers: |
IRB00044228 1U01DC013778-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | June 29, 2015 Key Record Dates |
Last Update Posted: | August 12, 2022 |
Last Verified: | August 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Vertigo Dizziness Unsteadiness Stroke Vestibular neuritis |
Benign paroxysmal positional vertigo Vestibulo-ocular reflex Video-oculography Emergency department |
Vertigo Emergencies Dizziness Disease Attributes Pathologic Processes Vestibular Diseases |
Labyrinth Diseases Ear Diseases Otorhinolaryngologic Diseases Neurologic Manifestations Nervous System Diseases Sensation Disorders |